Physician profile
Bernard Dib
NPI 1770979049
$3,657.79
in general payments reported to CMS, 2019-2025
15 companies · $615 in 2025
The $615 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,100 · 2021: $343 · 2022: $461 · 2023: $551 · 2024: $588 · 2025: $615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,754.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,353.99 | 2019-2024 | Clareon, Constellation |
| Genentech USA, INC. | $597.96 | 2021-2025 | Vabysmo |
| Glaukos Corporation | $367.95 | 2022-2024 | Istent Infinite Trabecular Micro-Bypass System Model Is3, Ce-Marked Kxla System |
| Regeneron Healthcare Solutions, INC. | $273.76 | 2021-2025 | Eylea Hd, Eylea |
| Astellas Pharma US INC | $250.65 | 2024-2025 | Izervay |
| Abbvie INC. | $229.91 | 2022-2025 | |
| Genentech, INC. | $164.33 | 2025 | Vabysmo |
| Alimera Sciences, INC. | $124.03 | 2021-2024 | Iluvien, Yutiq |
| Apellis Pharmaceuticals, INC. | $80.75 | 2025 | Syfovre |
| Biogen, INC. | $79.80 | 2022 | |
| Ani Pharmaceuticals, INC. | $53.21 | 2024-2025 | Purified Cortrophin Gel |
| Eyepoint US, INC. | $24.20 | 2022 | |
| Bausch & Lomb Americas INC. | $20.53 | 2022 | |
| Dompe US, INC. | $20.15 | 2022 | |
| Thea Pharma INC. | $16.57 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernard Dib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.